Aamc
Upcoming News Article: WEB Moderna's KP2 Vaccine Shows Promise Against New COVID-19 Variants
Effective Protection Against JN Variants
In a study conducted by WEB Moderna, the company's KP2 vaccine has demonstrated remarkable efficacy against JN variants of the COVID-19 virus. Compared to the XBB15 vaccine, the KP2 vaccine was found to be up to eight times more effective in protecting mice against infection. This finding suggests that the KP2 vaccine holds great promise in safeguarding individuals against the evolving variants of COVID-19.
Updated Monovalent Vaccines
Drug manufacturers have recently developed updated monovalent COVID-19 vaccines tailored to combat the currently circulating variants. These vaccines are designed to provide enhanced protection against the new strains and are recommended for individuals who have previously been vaccinated with a COVID vaccine.
Eligibility and Effectiveness
Individuals 12 years of age and older who have completed their primary COVID vaccine series and have not received an updated vaccine are eligible to receive the updated monovalent vaccine. Studies have shown that these vaccines are highly effective in preventing COVID-19, including against the predominant Omicron subvariants.
Additional Data
Recently released data from the Centers for Disease Control and Prevention (CDC) indicates that the updated COVID-19 vaccines have been effective in preventing COVID-19 during the period of September 2023 to January 2024. The vaccines have also shown efficacy against the newer Omicron subvariants that have emerged during this time.
Pew Research Center
Komentar